Prestige Consumer Healthcare Inc. logo

Prestige Consumer Healthcare Inc.

PBH

NYSEHealthcareMedical - Pharmaceuticals

Previous close

$51.31

+$0.79 · +1.56%

Aug 21, 4:00 PM ET

PBH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

83

Deep Value

Momentum

30

Weakening

Sentiment

52

Mixed

Risk resilience

58

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
US
CEO
Ronald Lombardi
Listed since
Feb 10, 2005
Employees
890

Market position

Day range

Current $51.31

52-week range

Current $51.31

Open
$50.21
Previous close
$50.52
Volume
265.12K
0.41× average
Average volume
642.83K
Average daily volume
Market cap
2.43B USD
Beta
0.33
Market reference 1
50-day average
$49.6846
+3.27% above average
200-day average
$57.204
-10.30% below average

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+0.08%
11 comparable reports
Latest EPS result
0.98
Estimate 0.89 · Beat by 9.62%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.451.241.040.84Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 1.22, estimate 1.16, surprise +5.17%, Beat. Q2 2025, reported May 8, 2025: actual 1.32, estimate 1.3, surprise +1.54%, Beat. Q3 2025, reported Aug 7, 2025: actual 0.95, estimate 1.01, surprise -5.94%, Miss. Q4 2025, reported Nov 6, 2025: actual 1.07, estimate 0.97, surprise +10.31%, Beat. Q1 2026, reported Feb 5, 2026: actual 1.14, estimate 1.16, surprise -1.72%, Miss. Q2 2026, reported May 13, 2026: actual 1.23, estimate 1.39, surprise -11.51%, Miss. Q3 2026, reported Aug 6, 2026: actual 0.98, estimate 0.894, surprise +9.62%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates342.32M307M271.68M236.36MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 290.32M USD, estimate 289.81M USD, surprise +0.18%, Beat. Q2 2025, reported May 8, 2025: actual 296.76M USD, estimate 270.41M USD, surprise +9.74%, Beat. Q3 2025, reported Aug 7, 2025: actual 249.53M USD, estimate 275M USD, surprise -9.26%, Miss. Q4 2025, reported Nov 6, 2025: actual 274.11M USD, estimate 294.15M USD, surprise -6.81%, Miss. Q1 2026, reported Feb 5, 2026: actual 283.44M USD, estimate 282.21M USD, surprise +0.44%, Beat. Q2 2026, reported May 13, 2026: actual 281.62M USD, estimate 293.64M USD, surprise -4.09%, Miss. Q3 2026, reported Aug 6, 2026: actual 265.71M USD, estimate 253.02M USD, surprise +5.01%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 329.15M USD, surprise —, Comparison unavailable.

PBH news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.475

2018 complete year+52.0% since 2013

Corporate action history

Dividend

Ex-dividend Sep 27, 2018

$0.475

Special

Payment Oct 15, 2018

Dividend

Ex-dividend Dec 27, 2013

$0.3125

Special

PBH peers

ETFs holding PBH

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research PBH

research.disclaimer